PROCEPT BioRobotics (PRCT) Stock Overview
A surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PRCT Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
PROCEPT BioRobotics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$33.00 |
| 52 Week High | US$103.81 |
| 52 Week Low | US$32.46 |
| Beta | 0.99 |
| 1 Month Change | -11.15% |
| 3 Month Change | -43.11% |
| 1 Year Change | -54.79% |
| 3 Year Change | -18.20% |
| 5 Year Change | n/a |
| Change since IPO | -21.32% |
Recent News & Updates
Is PROCEPT BioRobotics (NASDAQ:PRCT) A Risky Investment?
Sep 26
Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy
Aug 14What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S After Its 34% Share Price Crash
Aug 09PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$65.75 Price Target
Aug 08Recent updates
Is PROCEPT BioRobotics (NASDAQ:PRCT) A Risky Investment?
Sep 26Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy
Aug 14What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S After Its 34% Share Price Crash
Aug 09PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$65.75 Price Target
Aug 08US$77.00: That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After Its Latest Results
Apr 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects
Apr 18
HYDROS Robotic System Launch And Aquablation Trials Will Drive Future Market Expansion
Launch of HYDROS Robotic System and FDA approvals likely to increase procedural adoption and drive revenue growth.Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
Mar 11PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$93.86 Price Target
Feb 28What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S
Dec 05Procept BioRobotics: Continued Growth Runway Ahead
Nov 26Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102
Oct 31Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth
Sep 12Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
May 21The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Apr 05US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
Feb 07Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
Dec 14Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?
Feb 27Shareholder Returns
| PRCT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.4% | -2.2% | -1.3% |
| 1Y | -54.8% | -3.5% | 14.4% |
Return vs Industry: PRCT underperformed the US Medical Equipment industry which returned -3% over the past year.
Return vs Market: PRCT underperformed the US Market which returned 13.4% over the past year.
Price Volatility
| PRCT volatility | |
|---|---|
| PRCT Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRCT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PRCT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 756 | Larry Wood | www.procept-biorobotics.com |
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.
PROCEPT BioRobotics Corporation Fundamentals Summary
| PRCT fundamental statistics | |
|---|---|
| Market cap | US$1.83b |
| Earnings (TTM) | -US$84.15m |
| Revenue (TTM) | US$274.95m |
Is PRCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRCT income statement (TTM) | |
|---|---|
| Revenue | US$274.95m |
| Cost of Revenue | US$98.46m |
| Gross Profit | US$176.49m |
| Other Expenses | US$260.64m |
| Earnings | -US$84.15m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 64.19% |
| Net Profit Margin | -30.60% |
| Debt/Equity Ratio | 13.4% |
How did PRCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/13 21:22 |
| End of Day Share Price | 2025/10/13 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PROCEPT BioRobotics Corporation is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Craig Bijou | BofA Global Research |
| Neil Chatterji | B. Riley Securities, Inc. |